The Effects of Rifaximin Therapy in Irritable Bowel Syndrome

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of Rifaximin therapy started prior to completion of advanced examination procedure (before colonoscopy) of patients pre-diagnosed with irritable bowel syndrome, and implement it into clinical practice.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bezmialem Vakif University
• Treatments: Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• Patients between the ages of 18 and 50 years without alarm symptoms, who were examined at the Gastroenterology Clinic, without endoscopic assessment, due to complaints of Irritable Bowel Syndrome, and pre-diagnosed with Irritable Bowel Syndrome according to the Rome III criteria, will be included in the study.

Exclusion Criteria:

1. are under the age of 18 years,

2. are allergic to Rifaximin,

3. are pregnant and lactating,

4. have documented diseases of the gastrointestinal system (such as gastric and duodenal ulcers, gastric cancer, small intestine and colon cancer, inflammatory bowel disease [Crohn's and Ulcerative Colitis], gastroparesis, chronic intestinal ischemia, etc.),

5. have (describe) documented diseases of the pancreas, biliary tract, and liver (such as pancreatitis, biliary colic pain associated with gallstones, acute cholecystitis, choledochal stone, hepatitis, hepatobiliary cancers, etc.),

6. have previously undergone major abdominal surgery,

7. have a systemic disease (such as collagen tissue disorders, kidney dysfunction, systemic infection, etc.),

8. have an identified psychiatric disorder,

and/or

9. consume alcohol excessively